+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

NHL: Follicular Lymphoma Forecast and Market Analysis (FL) to 2026

  • ID: 3797464
  • Drug Pipelines
  • 510 pages
  • Datamonitor Healthcare
1 of 2
Disease Overview
Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL). It is the second most common type of NHL after diffuse large B-cell lymphoma (DLBCL), and accounts for more than 20% of all NHL cases. The disease is staged based on the percentage of large cells occurring within the malignant B lymphocytes. Low grades of FL are generally characterized by slow progression of the disease. Patients can be managed successfully to prolong remission times and extend survival, but the disease is mostly incurable. In contrast, higher grades of FL tend to become more aggressive in nature and require timely treatment.

Recent events and opinion
  • Driven by approvals of new drugs in later lines, the follicular lymphoma market is set to reach $3.9bn in value by 2026.
  • The author’s survey of 223 medical hematologists and hemato-oncologists sheds light on prescribing trends in follicular lymphoma.
  • Incident cases of the three major subtypes of NHL will increase by at least a quarter over the forecast period.
  • Branded drugs Rituxan and Treanda/Bendeka will continue to be crucial to the treatment paradigm.
  • Drug development in follicular lymphoma predominately targets the relapsed/refractory setting.
Note: Product cover images may vary from those shown
2 of 2
FORECAST: FOLLICULAR LYMPHOMA (Published on 30 January 2019)
Overview
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Aliqopa
Product Profile (Late Stage): Betalutin
Product Profile: Copiktra
Product Profile: Gazyva
Product Profile (Late Stage): Incb050465
Product Profile (Late Stage): Imbruvica
Product Profile (Late Stage): Kymriah
Product Profile (Late Stage): Revlimid
Product Profile: Rituxan
Product Profile: Treanda/Bendeka
Product Profile (Late Stage): Yescarta
Product Profile: Zevalin
Product Profile: Zydelig
Product Profile (Late Stage): Lisocabtagene Maraleucel
Product Profile (Late Stage): Ublituximab
Product Profile (Late Stage): Umbralisib
Product Profile (Late Stage): Zanubrutinib

TREATMENT: FOLLICULAR LYMPHOMA (Published on 30 January 2019)
Overview
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources

MARKETED DRUGS: FOLLICULAR LYMPHOMA (Published on 30 January 2019)
Overview
Product Overview
Product Profile: Aliqopa
Product Profile: Copiktra
Product Profile: Gazyva
Product Profile: Rituxan
Product Profile: Treanda/Bendeka
Product Profile: Zevalin
Product Profile: Zydelig

PIPELINE: FOLLICULAR LYMPHOMA (Published on 30 January 2019)
Overview
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Betalutin
Product Profile (Late Stage): Incb050465
Product Profile (Late Stage): Imbruvica
Product Profile (Late Stage): Kymriah
Product Profile (Late Stage): Revlimid
Product Profile (Late Stage): Yescarta
Product Profile (Late Stage): Lisocabtagene Maraleucel
Product Profile (Late Stage): Ublituximab
Product Profile (Late Stage): Umbralisib
Product Profile (Late Stage): Zanubrutinib

LIST OF FIGURES
Figure 1: Follicular lymphoma – current and future market dynamics analysis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for follicular lymphoma
Figure 3: Follicular lymphoma market value across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Follicular lymphoma market value across the US, Japan, and five major EU markets, by class, 2017–26
Figure 5: Sales of CAR-T therapies for follicular lymphoma across the US, Japan, and five major EU markets, by product, 2017–26
Figure 6: Sales of branded Rituxan and biosimilar rituximab for follicular lymphoma across the US, Japan, and five major EU markets, by product, 2017–26
Figure 7: Sales of PI3K inhibitors for follicular lymphoma across the US, Japan, and five major EU markets, by product, 2017–26
Figure 8: Sales of Revlimid, Imbruvica, and Betalutin for follicular lymphoma across the US, Japan, and five major EU markets, by brand, 2017–26
Figure 9: Patient-based forecast methodology for follicular lymphoma
Figure 10: Price sources and calculations, by country
Figure 11: Aliqopa for follicular lymphoma – SWOT analysis
Figure 12: The authors drug assessment summary of Aliqopa for follicular lymphoma
Figure 13: The authors drug assessment summary of Aliqopa for follicular lymphoma
Figure 14: Aliqopa sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 15: Betalutin for follicular lymphoma – SWOT analysis
Figure 16: The authors drug assessment summary of Betalutin for follicular lymphoma
Figure 17: The authors drug assessment summary of Betalutin for follicular lymphoma
Figure 18: Betalutin sales for follicular lymphoma across the US and five major EU markets, by country, 2017–26
Figure 19: Copiktra for follicular lymphoma – SWOT analysis
Figure 20: The authors drug assessment summary of Copiktra for follicular lymphoma
Figure 21: The authors drug assessment summary of Copiktra for follicular lymphoma
Figure 22: Copiktra sales for follicular lymphoma across the US and five major EU markets, by country, 2017–26
Figure 23: Gazyva for follicular lymphoma – SWOT analysis
Figure 24: The authors drug assessment summary of Gazyva for follicular lymphoma
Figure 25: The authors drug assessment summary of Gazyva for follicular lymphoma
Figure 26: Gazyva sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 27: INCB050465 for follicular lymphoma – SWOT analysis
Figure 28: The authors drug assessment summary of INCB050465 for follicular lymphoma
Figure 29: The authors drug assessment summary of INCB050465 for follicular lymphoma
Figure 30: INCB050465 sales for follicular lymphoma in the US, 2017–26
Figure 31: Imbruvica for follicular lymphoma – SWOT analysis
Figure 32: The authors drug assessment summary of Imbruvica for follicular lymphoma
Figure 33: The authors drug assessment summary for Imbruvica in follicular lymphoma
Figure 34: Imbruvica sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 35: Kymriah for follicular lymphoma – SWOT analysis
Figure 36: The authors drug assessment summary of Kymriah for follicular lymphoma
Figure 37: The authors drug assessment summary of Kymriah for follicular lymphoma
Figure 38: Kymriah sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 39: Revlimid for follicular lymphoma – SWOT analysis
Figure 40: The authors drug assessment summary of Revlimid for follicular lymphoma
Figure 41: The authors drug assessment summary of Revlimid for follicular lymphoma
Figure 42: Revlimid sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 43: Rituxan for follicular lymphoma – SWOT analysis
Figure 44: The authors drug assessment summary of Rituxan for follicular lymphoma
Figure 45: The authors drug assessment summary of Rituxan for follicular lymphoma
Figure 46: Rituxan sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 47: Treanda/Bendeka for follicular lymphoma – SWOT analysis
Figure 48: The authors drug assessment summary of Treanda/Bendeka for follicular lymphoma
Figure 49: The authors drug assessment summary of Treanda/Bendeka for follicular lymphoma
Figure 50: Treanda/Bendeka sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 51: Yescarta for follicular lymphoma – SWOT analysis
Figure 52: The authors drug assessment summary of Yescarta for follicular lymphoma
Figure 53: The authors drug assessment summary of Yescarta for follicular lymphoma
Figure 54: Yescarta sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 55: Zevalin for follicular lymphoma – SWOT analysis
Figure 56: The authors drug assessment summary of Zevalin for follicular lymphoma
Figure 57: The authors drug assessment summary of Zevalin for follicular lymphoma
Figure 58: Zevalin sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 59: Zydelig for follicular lymphoma – SWOT analysis
Figure 60: The authors drug assessment summary of Zydelig for follicular lymphoma
Figure 61: The authors drug assessment summary of Zydelig for follicular lymphoma
Figure 62: Zydelig sales for follicular lymphoma across the US and five major EU markets, by country, 2017–26
Figure 63: Lisocabtagene maraleucel for follicular lymphoma – SWOT analysis
Figure 64: The authors drug assessment summary of lisocabtagene maraleucel for follicular lymphoma
Figure 65: The authors drug assessment summary of lisocabtagene maraleucel for follicular lymphoma
Figure 66: Lisocabtagene maraleucel sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 67: Ublituximab for follicular lymphoma – SWOT analysis
Figure 68: The authors drug assessment summary of ublituximab for follicular lymphoma
Figure 69: The authors drug assessment summary of ublituximab for follicular lymphoma
Figure 70: Ublituximab sales for follicular lymphoma across the US and five major EU markets, by country, 2017–26
Figure 71: Umbralisib for follicular lymphoma – SWOT analysis
Figure 72: The authors drug assessment summary of umbralisib for follicular lymphoma
Figure 73: The authors drug assessment summary of umbralisib for follicular lymphoma
Figure 74: Umbralisib sales for follicular lymphoma across the US and five major EU markets, by country, 2017–26
Figure 75: Zanubrutinib for follicular lymphoma – SWOT analysis
Figure 76: The authors drug assessment summary of zanubrutinib for follicular lymphoma
Figure 77: The authors drug assessment summary of zanubrutinib for follicular lymphoma
Figure 78: Zanubrutinib sales for follicular lymphoma across the US and five major EU markets, by country, 2017–26
Figure 79: Proportion of follicular lymphoma diagnosed at localized and bulky stages of disease, by country (%)
Figure 80: Proportion of localized-stage (I/II) patients in each treatment category, by country (%)
Figure 81: Proportion of localized-stage (I/II) patients receiving each treatment type, by country (%)
Figure 82: Proportions of localized-stage (I/II) follicular lymphoma patients receiving first-line induction therapies, by country (%)
Figure 83: Proportions of localized-stage (I/II) follicular lymphoma patients receiving first-line maintenance therapies, by country (%)
Figure 84: Proportions of localized-stage (I/II) follicular lymphoma patients receiving second-line therapies, by country (%)
Figure 85: Proportions of localized-stage (I/II) follicular lymphoma patients receiving second-line maintenance therapies, by country (%)
Figure 86: Proportions of localized-stage (I/II) follicular lymphoma patients receiving third-line therapies, by country (%)
Figure 87: Proportions of localized-stage (I/II) follicular lymphoma patients receiving third-line maintenance therapies, by country (%)
Figure 88: Proportion of bulky-stage (II/III/IV) patients in each treatment category, by country (%)
Figure 89: Proportion of bulky-stage (II/III/IV) patients receiving each treatment type, by country (%)
Figure 90: Proportions of bulky-stage (II/III/IV) follicular lymphoma patients receiving first-line induction therapies, by country (%)
Figure 91: Proportions of bulky-stage (II/III/IV) follicular lymphoma patients receiving first-line maintenance therapies, by country (%)
Figure 92: Trends in incident cases of NHL in the US, Japan, and five major EU markets, 2017–37
Figure 93: Trends in incident cases of DLBCL in the US, Japan, and five major EU markets, 2017–37
Figure 94: Trends in incident cases of FL in the US, Japan, and five major EU markets, 2017–37
Figure 95: Trends in incident cases of MCL in the US, Japan, and five major EU markets, 2017–37
Figure 96: Aliqopa for follicular lymphoma – SWOT analysis
Figure 97: The authors drug assessment summary of Aliqopa for follicular lymphoma
Figure 98: The authors drug assessment summary of Aliqopa for follicular lymphoma
Figure 99: Aliqopa sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 100: Copiktra for follicular lymphoma – SWOT analysis
Figure 101: The authors drug assessment summary of Copiktra for follicular lymphoma
Figure 102: The authors drug assessment summary of Copiktra for follicular lymphoma
Figure 103: Copiktra sales for follicular lymphoma across the US and five major EU markets, by country, 2017–26
Figure 104: Gazyva for follicular lymphoma – SWOT analysis
Figure 105: The authors drug assessment summary of Gazyva for follicular lymphoma
Figure 106: The authors drug assessment summary of Gazyva for follicular lymphoma
Figure 107: Gazyva sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 108: Rituxan for follicular lymphoma – SWOT analysis
Figure 109: The authors drug assessment summary of Rituxan for follicular lymphoma
Figure 110: The authors drug assessment summary of Rituxan for follicular lymphoma
Figure 111: Rituxan sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 112: Treanda/Bendeka for follicular lymphoma – SWOT analysis
Figure 113: The authors drug assessment summary of Treanda/Bendeka for follicular lymphoma
Figure 114: The authors drug assessment summary of Treanda/Bendeka for follicular lymphoma
Figure 115: Treanda/Bendeka sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 116: Zevalin for follicular lymphoma – SWOT analysis
Figure 117: The authors drug assessment summary of Zevalin for follicular lymphoma
Figure 118: The authors drug assessment summary of Zevalin for follicular lymphoma
Figure 119: Zevalin sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 120: Zydelig for follicular lymphoma – SWOT analysis
Figure 121: The authors drug assessment summary of Zydelig for follicular lymphoma
Figure 122: The authors drug assessment summary of Zydelig for follicular lymphoma
Figure 123: Zydelig sales for follicular lymphoma across the US and five major EU markets, by country, 2017–26
Figure 124: Betalutin for follicular lymphoma – SWOT analysis
Figure 125: The authors drug assessment summary of Betalutin for follicular lymphoma
Figure 126: The authors drug assessment summary of Betalutin for follicular lymphoma
Figure 127: Betalutin sales for follicular lymphoma across the US and five major EU markets, by country, 2017–26
Figure 128: INCB050465 for follicular lymphoma – SWOT analysis
Figure 129: The authors drug assessment summary of INCB050465 for follicular lymphoma
Figure 130: The authors drug assessment summary of INCB050465 for follicular lymphoma
Figure 131: INCB050465 sales for follicular lymphoma in the US, 2017–26
Figure 132: Imbruvica for follicular lymphoma – SWOT analysis
Figure 133: The authors drug assessment summary of Imbruvica for follicular lymphoma
Figure 134: The authors drug assessment summary for Imbruvica in follicular lymphoma
Figure 135: Imbruvica sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 136: Kymriah for follicular lymphoma – SWOT analysis
Figure 137: The authors drug assessment summary of Kymriah for follicular lymphoma
Figure 138: The authors drug assessment summary of Kymriah for follicular lymphoma
Figure 139: Kymriah sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 140: Revlimid for follicular lymphoma – SWOT analysis
Figure 141: The authors drug assessment summary of Revlimid for follicular lymphoma
Figure 142: The authors drug assessment summary of Revlimid for follicular lymphoma
Figure 143: Revlimid sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 144: Yescarta for follicular lymphoma – SWOT analysis
Figure 145: The authors drug assessment summary of Yescarta for follicular lymphoma
Figure 146: The authors drug assessment summary of Yescarta for follicular lymphoma
Figure 147: Yescarta sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 148: Lisocabtagene maraleucel for follicular lymphoma – SWOT analysis
Figure 149: The authors drug assessment summary of lisocabtagene maraleucel for follicular lymphoma
Figure 150: The authors drug assessment summary of lisocabtagene maraleucel for follicular lymphoma
Figure 151: Lisocabtagene maraleucel sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 152: Ublituximab for follicular lymphoma – SWOT analysis
Figure 153: The authors drug assessment summary of ublituximab for follicular lymphoma
Figure 154: The authors drug assessment summary of ublituximab for follicular lymphoma
Figure 155: Ublituximab sales for follicular lymphoma across the US and five major EU markets, by country, 2017–26
Figure 156: Umbralisib for follicular lymphoma – SWOT analysis
Figure 157: The authors drug assessment summary of umbralisib for follicular lymphoma
Figure 158: The authors drug assessment summary of umbralisib for follicular lymphoma
Figure 159: Umbralisib sales for follicular lymphoma across the US and five major EU markets, by country, 2017–26
Figure 160: Zanubrutinib for follicular lymphoma – SWOT analysis
Figure 161: The authors drug assessment summary of zanubrutinib for follicular lymphoma
Figure 162: The authors drug assessment summary of zanubrutinib for follicular lymphoma
Figure 163: Zanubrutinib sales for follicular lymphoma across the US and five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: Follicular lymphoma market value across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 2: Follicular lymphoma market value across the US, Japan, and five major EU markets, by class and product ($m), 2017–26
Table 3: Sales of CAR-T therapies for follicular lymphoma across the US, Japan, and five major EU markets, by product ($m), 2017–26
Table 4: Sales of branded Rituxan and biosimilar rituximab for follicular lymphoma across the US, Japan, and five major EU markets, by product ($m), 2017–26
Table 5: Sales of PI3K inhibitors for follicular lymphoma across the US, Japan, and five major EU markets, by product ($m), 2017–26
Table 6: Sales of Revlimid, Imbruvica, and Betalutin for follicular lymphoma across the US, Japan, and five major EU markets, by brand ($m), 2017–26
Table 7: Exchange rates used for calculating prices
Table 8: Physicians surveyed for the follicular lymphoma primary research study
Table 9: Aliqopa drug profile
Table 10: Aliqopa pivotal trial data in follicular lymphoma
Table 11: Aliqopa ongoing late-phase clinical trials in follicular lymphoma
Table 12: Aliqopa sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 13: Betalutin drug profile
Table 14: Betalutin ongoing pivotal clinical trial in follicular lymphoma
Table 15: Betalutin clinical trial data in follicular lymphoma
Table 16: Betalutin sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 17: Copiktra drug profile
Table 18: Copiktra pivotal trial data in follicular lymphoma
Table 19: Copiktra sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 20: Gazyva drug profile
Table 21: Gazyva pivotal trial data in follicular lymphoma
Table 22: Gazyva other clinical trials in follicular lymphoma
Table 23: Gazyva ongoing late-phase clinical trials in follicular lymphoma
Table 24: Gazyva sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 25: INCB050465 drug profile
Table 26: INCB050465 ongoing pivotal trial in follicular lymphoma
Table 27: INCB050465 clinical trial data in follicular lymphoma
Table 28: INCB050465 sales for follicular lymphoma in the US ($m), 2017–26
Table 29: Imbruvica – drug profile
Table 30: Imbruvica ongoing pivotal trial in follicular lymphoma
Table 31: Imbruvica clinical trial data in follicular lymphoma
Table 32: Imbruvica sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 33: Kymriah drug profile
Table 34: Kymriah Phase IIa trial in follicular lymphoma
Table 35: Kymriah clinical trial data in follicular lymphoma
Table 36: Kymriah sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 37: Revlimid drug profile
Table 38: Revlimid pivotal trial data in follicular lymphoma
Table 39: Revlimid sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 40: Rituxan drug profile
Table 41: Rituxan pivotal trial data in follicular lymphoma
Table 42: Rituxan other clinical trial data in follicular lymphoma
Table 43: Rituxan sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 44: Treanda/Bendeka drug profile
Table 45: Treanda/Bendeka pivotal trial data in follicular lymphoma
Table 46: Treanda/Bendeka other clinical trial data in follicular lymphoma
Table 47: Treanda/Bendeka sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 48: Yescarta drug profile
Table 49: Yescarta ongoing pivotal trial in follicular lymphoma
Table 50: Yescarta sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 51: Zevalin drug profile
Table 52: Zevalin pivotal trial data in follicular lymphoma
Table 53: Zevalin Phase II clinical trial in follicular lymphoma
Table 54: Zevalin sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 55: Zydelig drug profile
Table 56: Zydelig pivotal trial data in follicular lymphoma
Table 57: Zydelig sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 58: Lisocabtagene maraleucel drug profile
Table 59: Lisocabtagene maraleucel ongoing pivotal trial in follicular lymphoma
Table 60: Lisocabtagene maraleucel sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 61: Ublituximab drug profile
Table 62: Ublituximab ongoing pivotal trial in follicular lymphoma
Table 63: Ublituximab sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 64: Umbralisib drug profile
Table 65: Umbralisib ongoing pivotal trials in follicular lymphoma
Table 66: Umbralisib clinical trial data in follicular lymphoma
Table 67: Umbralisib sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 68: Zanubrutinib drug profile
Table 69: Zanubrutinib ongoing late-phase clinical trial in follicular lymphoma
Table 70: Zanubrutinib sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 71: Physicians surveyed for the follicular lymphoma primary research study, 2016
Table 72: US percentage distribution of cases and five-year observed survival rates for follicular lymphoma, by stage
Table 73: Ann Arbor stage classification
Table 74: Revised staging system for primary nodal lymphomas
Table 75: Targeted drugs for the treatment of follicular lymphoma
Table 76: Main cytotoxic therapies for the treatment of follicular lymphoma
Table 77: Cancer registry databases used as a source of NHL, DLBCL, FL, and MCL incidence data, by country
Table 78: Ann Arbor classification system
Table 79: Incident cases of NHL in the US, Japan, and five major EU markets, 2017–37
Table 80: Incident cases of DLBCL in the US, Japan, and five major EU markets, 2017–37
Table 81: Incident cases of FL in the US, Japan, and five major EU markets, 2017–37
Table 82: Incident cases of MCL in the US, Japan, and five major EU markets, 2017–37
Table 83: Profiled key marketed drugs for follicular lymphoma
Table 84: Aliqopa drug profile
Table 85: Aliqopa pivotal trial data in follicular lymphoma
Table 86: Aliqopa ongoing late-phase clinical trials in follicular lymphoma
Table 87: Aliqopa sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 88: Copiktra drug profile
Table 89: Copiktra pivotal trial data in follicular lymphoma
Table 90: Copiktra sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 91: Gazyva drug profile
Table 92: Gazyva pivotal trial data in follicular lymphoma
Table 93: Gazyva other clinical trials in follicular lymphoma
Table 94: Gazyva ongoing late-phase clinical trials in follicular lymphoma
Table 95: Gazyva sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 96: Rituxan drug profile
Table 97: Rituxan pivotal trial data in follicular lymphoma
Table 98: Rituxan other clinical trial data in follicular lymphoma
Table 99: Rituxan sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 100: Treanda/Bendeka drug profile
Table 101: Treanda/Bendeka pivotal trial data in follicular lymphoma
Table 102: Treanda/Bendeka other clinical trial data in follicular lymphoma
Table 103: Treanda/Bendeka sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 104: Zevalin drug profile
Table 105: Zevalin pivotal trial data in follicular lymphoma
Table 106: Zevalin Phase II clinical trial in follicular lymphoma
Table 107: Zevalin sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 108: Zydelig drug profile
Table 109: Zydelig pivotal trial data in follicular lymphoma
Table 110: Zydelig sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 111: Profiled pipeline products in development for follicular lymphoma
Table 112: Betalutin drug profile
Table 113: Betalutin ongoing pivotal clinical trial in follicular lymphoma
Table 114: Betalutin clinical trial data in follicular lymphoma
Table 115: Betalutin sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 116: INCB050465 drug profile
Table 117: INCB050465 ongoing pivotal trial in follicular lymphoma
Table 118: INCB050465 clinical trial data in follicular lymphoma
Table 119: INCB050465 sales for follicular lymphoma in the US ($m), 2017–26
Table 120: Imbruvica – drug profile
Table 121: Imbruvica ongoing pivotal trial in follicular lymphoma
Table 122: Imbruvica clinical trial data in follicular lymphoma
Table 123: Imbruvica sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 124: Kymriah drug profile
Table 125: Kymriah Phase IIa trial in follicular lymphoma
Table 126: Kymriah clinical trial data in follicular lymphoma
Table 127: Kymriah sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 128: Revlimid drug profile
Table 129: Revlimid pivotal trial data in follicular lymphoma
Table 130: Revlimid sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 131: Yescarta drug profile
Table 132: Yescarta ongoing pivotal trial in follicular lymphoma
Table 133: Yescarta sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 134: Lisocabtagene maraleucel drug profile
Table 135: Lisocabtagene maraleucel ongoing pivotal trial in follicular lymphoma
Table 136: Lisocabtagene maraleucel sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 137: Ublituximab drug profile
Table 138: Ublituximab ongoing pivotal trial in follicular lymphoma
Table 139: Ublituximab sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 140: Umbralisib drug profile
Table 141: Umbralisib ongoing pivotal trials in follicular lymphoma
Table 142: Umbralisib clinical trial data in follicular lymphoma
Table 143: Umbralisib sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017–26
Table 144: Zanubrutinib drug profile
Table 145: Zanubrutinib ongoing late-phase clinical trial in follicular lymphoma
Table 146: Zanubrutinib sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017–26
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Order Online - visit: https://www.researchandmarkets.com/reports/3797464
Adroll
adroll